Endomag has also opened its new US office in Austin, Texas, in preparation for expansion into the American market.
The company has recently started a US trial of its Sentimag® and Sienna+® system for staging breast cancer and is expecting significant continued growth through international sales expansion. It is also developing a unique platform of devices that spans from the Sentimag® and Sienna+® system supporting diagnostics into systems for therapeutics following acquisition of the ACT portfolio last year.
Dr Eric Mayes, CEO at Endomag, said: “In December we revealed our new brand identity, and the new offices in both the UK and the US reflect a time of exciting change for Endomag as we look to expand into global markets.
“We’re looking forward to settling into our new premises, which has its own development lab, and starting a new chapter for Endomag as we take significant strategic steps in the development of our products. We believe the use of magnetics to support minimally invasive treatments has huge potential and we’re confident that our product platform offers simple and accessible solutions in cancer care.”
Endomag is dedicated to improving the global standard cancer care for everyone, everywhere, by developing a new, effective clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices.
Endomag’s first approved products are the Sentimag® and Sienna+®, CE-approved for marketing and sales in Europe, and TGA-approved for Australasia. Sienna+® is a magnetic tracer injected into the body and the Sentimag® is used to track its presence, locating lymph nodes as part of a sentinel lymph node biopsy (SLNB) procedure.
By avoiding the need for traditional radioactive isotopes in sentinel lymph node biopsy, Sentimag® and Sienna+® improve workflow and lower costs, enhance patient comfort and quality of life, and provide a better standard of care available to everyone, everywhere.
Visit www.endomag.com
*******
PR media contacts: Nicola Collenette/ Charlie Hopkinson
E: nicola.collenette@mobas.com / charlie.hopkinson@mobas.com
T: +44 (0)1223 841699 / +44(0)7711 372820
______________________________________